Public Release:  Announcing 3 special sessions during ARVO 2013 Annual Meeting

Sunday, May 5: Results from AREDS2 and Audacious Goals Update, Tuesday, May 7: Results from IVAN2 and GEFAL

Association for Research in Vision and Ophthalmology

Rockville, Md. -- The Association for Research in Vision and Ophthalmology is pleased to host three special sessions during the 2013 Annual Meeting (May 5 - 9) in Seattle, Wash. These sessions will take place at the Washington State Convention Center.

Results from the Age-Related Eye Disease Study 2 (AREDS2) from the National Eye Institute

Findings from a randomized, controlled clinical trial of lutein/zeaxanthin and omega-3 fatty acids for the treatment of age-related macular degeneration and cataract

Sunday, May 5, 2013, 4:15 - 5:15pm, Ballroom 6ABC

The results from this clinical trial will be published online in JAMA (the Journal of the American Medical Association) and JAMA Ophthalmology and embargoed until Sunday, May 5 at 7pm Eastern time to coincide with presentation at the ARVO 2013 Annual Meeting.

This session also will be streamed live. The livestream is free of charge, but advance registration is required. Please visit http://www.prolibraries.com/arvo/events/arvo2013/.

Presenters

Emily Chew, MD
Traci Clemons, PhD
Ronald Danis, MD
John Paul SanGiovanni, ScD

With an introduction by Paul Sieving, MD, PhD, director, National Eye Institute

The Age-Related Eye Disease Study 2 (AREDS2) Research Team will present the results of the multi-centered randomized controlled clinical trial of oral supplementation with lutein/zeaxanthin (10 mg/2mg) and/or omega-3 long-chain polyunsaturated fatty acids (LCPUFAs-1 g) for the treatment of age-related macular degeneration (AMD) and cataract.

This multi-centered trial was conducted in 82 clinical sites in the U.S., in both academic and community-based centers with retinal specialists from 2006 to 2012, in 4,203 participants, aged 50 - 85.

Ranibizumab versus Bevacizumab: Results from the IVAN2 and GEFAL Trials

Tuesday, May 7, 1 ‒ 2:30pm, Ballroom 6E

Session moderator: Daniel F. Martin, MD

IVAN Trial

Introduction: Usha Chakravarthy , MBBS, PhD, FARVO

Study Outcomes: Simon Harding, FRCOphth, MD

IVAN Panel Discussion: Usha Chakravarthy, MBBS, PhD, FARVO; Simon Harding, FRCOphth, MD; Chris Rogers

GEFAL Study

Overview: Laurent Kodjikian, MD, PhD

GEFAL Panel Discussion: Eric Souied, MD, PhD; Laure Huot; Evelyne Decullier; Laurent Kodjikian

Moderator: Daniel F. Martin, MD

Summary Panel Discussion: Comparative effectiveness of Ranibizumab versus Bevacizumab

NEI Audacious Goals Initiative in Vision Research and Blindness Rehabilitation

Sunday, May 5, 12:15 - 1pm, Ballroom 6E

NEI Director Paul A. Sieving, MD, PhD, will describe development of the NEI Audacious Goals Initiative, announce the goals and high priority areas and discuss implementation.

###

For information or to register for the ARVO 2013 Annual Meeting, visit http://www.arvo.org/am.

The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include over 12,000 eye and vision researchers from over 80 countries. ARVO encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology.

http://www.arvo.org

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.